What is the life expectancy of someone with 22q13 deletion / Phelan-McDermid Syndrome?

There is currently no definitive data suggesting that 22q13 deletion / Phelan-McDermid Syndrome significantly reduces life expectancy for the majority of individuals, as many adults with the condition are living into middle age and beyond. While the prognosis for 22q13 deletion / Phelan-McDermid Syndrome varies widely depending on the specific size of the genetic deletion and the presence of associated medical complications, consistent clinical care and symptom management are key to supporting long-term health and well-being.

What factors influence the long-term outlook for Phelan-McDermid Syndrome?

The clinical presentation of 22q13 deletion / Phelan-McDermid Syndrome is highly variable, which makes predicting an individual’s long-term path challenging. The size and location of the deletion on the 22q13.3 chromosome region play a significant role in determining the severity of developmental delays and physical symptoms. Factors that influence a patient's long-term health include the presence of severe epilepsy, kidney abnormalities, or cardiac issues. When these specific comorbidities are monitored and managed proactively by a multidisciplinary medical team, individuals with 22q13 deletion / Phelan-McDermid Syndrome often maintain a stable quality of life throughout adulthood.

How do early diagnosis and ongoing care improve outcomes?

Advances in genetic testing and increased clinical awareness have led to earlier diagnosis of 22q13 deletion / Phelan-McDermid Syndrome, allowing for earlier intervention. Early enrollment in physical, occupational, and speech therapies can significantly improve functional independence. Regular medical follow-up is vital; because this syndrome can affect multiple body systems, a proactive approach to screening—particularly for gastrointestinal, renal, and neurological health—helps prevent secondary complications that could otherwise impact longevity or daily comfort.

What should families know about quality of life?

While longevity is an important medical marker, quality of life remains the primary focus for our community of 35 families on DiseaseMaps.org who are navigating 22q13 deletion / Phelan-McDermid Syndrome. Many individuals with this condition lead fulfilling lives characterized by meaningful social interactions and the development of unique communication skills, even in the presence of limited verbal speech. Focusing on adaptive communication tools, sensory integration, and inclusive social environments can drastically enhance the daily experience of someone living with 22q13 deletion / Phelan-McDermid Syndrome.

Key areas for proactive medical management

To support the best possible long-term outcomes, experts recommend maintaining a consistent care plan that addresses the following:

• Neurological monitoring: Regular EEG screenings if seizures are present or suspected.


• Renal and cardiac health: Baseline and periodic ultrasounds to monitor for structural abnormalities.


• Gastrointestinal support: Managing chronic constipation or reflux, which are common and can significantly impact quality of life.


• Behavioral therapies: Ongoing support to manage sensory sensitivities and promote adaptive social behaviors.


• Multidisciplinary coordination: Ensuring communication between specialists (geneticists, neurologists, and primary care physicians).

Next steps

• Consult with a clinical geneticist to understand the specific nature of the deletion.


• Connect with the 35 members on DiseaseMaps.org to share experiences and peer support.


• Register with the Phelan-McDermid Syndrome Foundation (PMSF) to stay informed about the latest research and clinical trials.


• Establish a "medical home" where a primary care physician can coordinate care across multiple specialists.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; please consult a qualified healthcare provider for personal health concerns.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Phelan-McDermid syndrome.


• Orphanet: 22q13.3 deletion syndrome.


• Phelan-McDermid Syndrome Foundation (PMSF): Clinical resources and management guidelines.


• OMIM (Online Mendelian Inheritance in Man): 22q13.3 deletion syndrome.